MiNK Therapeutics (INKT) to Release Quarterly Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. On average, analysts expect MiNK Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiNK Therapeutics Stock Performance

NASDAQ INKT opened at $0.75 on Tuesday. The stock has a market cap of $29.66 million, a PE ratio of -1.53 and a beta of 0.05. The firm has a 50-day moving average of $0.74 and a 200-day moving average of $0.86. MiNK Therapeutics has a 52-week low of $0.57 and a 52-week high of $1.90.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of MiNK Therapeutics in a research report on Wednesday, October 9th.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.